Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD/MAD Study of REM0046127 in Healthy Subjects
NCT04672135Phase 1Completed
- Sponsor
- reMYND
- Start
- Nov 2020
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Alzheimer's disease (AD) comparing REM0046127 with Placebo (2 arms). Primary endpoints: Adverse Events, Peak Plasma Concentration and 3 more. Started Nov 2020; status: completed.
02
Drugs
rem0046127
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04672135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04672135.